What should I do if I become resistant to Pazopanib?

Pazopanib(Pazopanib) has been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of advanced renal cancer and soft tissue sarcoma (STS). It is a synthetic indazolyl pyrimidine and a new multi-target TKI that can interfere with a variety of tumor environmental factors that play a key role in multiple tumor types.

Pazopanib is a second-generation small molecule TKI with high affinity for VEGFR-1/2/3 and low affinity for PDGFR-α/β, FGFR-1/2 and stem cell factor receptor (c-KitR). If resistance develops after using pazopanib, your doctor may recommend genetic testing, tumor tissue examination, or other related examinations to understand your tumor type and resistance mechanism. Depending on your specific situation, your doctor may recommend switching to other targeted drugs or chemotherapy drugs. Sometimes one drug or treatment doesn't work well, but that doesn't mean other drugs won't work either.

PazopanibThe original drug has been launched in China and has entered the scope of Class B medical insurance, but reimbursement is limited to patients who meet the indications. The price of each box may be around 3,000 yuan. The price of pazopanib original drug specifications200mg*30 tablets marketed overseas may be around 1,000 RMB per box (the price may fluctuate due to exchange rates). There are also pazopanib generic drugs produced in other countries. The price of 200mg*30 tablets produced by Bangladesh pharmaceutical factory may be around 500 yuan per box (the price may fluctuate due to the exchange rate), which is cheaper. The pharmaceutical ingredients of generic drugs are basically the same as those of domestic and foreign original drugs.